淋巴瘤自体干细胞移植综述
A Review of Autologous Stem Cell Transplantation in Lymphoma.
作者信息
Zahid Umar, Akbar Faisal, Amaraneni Akshay, Husnain Muhammad, Chan Onyee, Riaz Irbaz Bin, McBride Ali, Iftikhar Ahmad, Anwer Faiz
机构信息
Department of Medicine, University of Arizona, Tucson, AZ, USA.
College of Public Health, University of Arizona, Tucson, AZ, USA.
出版信息
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1.
Abstract
PURPOSE OF REVIEW
Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.
RECENT FINDINGS
There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.
摘要
综述目的
化疗仍然是侵袭性淋巴瘤的一线治疗方法。然而，20%-30%的非霍奇金淋巴瘤（NHL）患者和15%的霍奇金淋巴瘤（HL）患者在初始治疗后会复发。我们想要探讨大剂量化疗（HDT）和自体干细胞移植（ASCT）在这些患者中的作用。
最新发现
对于高危/高级别B细胞淋巴瘤、套细胞淋巴瘤和T细胞淋巴瘤，前期巩固治疗有一定作用，但对HL没有类似干预作用。正在研究新的预处理方案，这些方案已证明在不影响复发或难治性HL的清髓效率的情况下安全性有所改善。挽救性化疗后进行HDT和救援自体干细胞移植仍然是复发/难治性淋巴瘤的标准治疗方法。新型药物在一线诱导、疾病挽救、大剂量巩固或维持治疗中改善疾病相关参数的作用仍有待阐明。
相似文献
1
A Review of Autologous Stem Cell Transplantation in Lymphoma.淋巴瘤自体干细胞移植综述
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1.
2
Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?新药在复发/难治性霍奇金淋巴瘤治疗中处于什么地位？
Curr Hematol Malig Rep. 2017 Jun;12(3):227-233. doi: 10.1007/s11899-017-0384-z.
3
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.大剂量化疗联合自体造血干细胞支持治疗复发或难治性原发性中枢神经系统淋巴瘤：德国合作 PCNSL 研究组的前瞻性多中心试验。
Leukemia. 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170. Epub 2017 May 31.
4
Y -Ibritumomab tiuxetan (Y -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).钇-伊布替膦酸（Y-IT）联合大剂量美法仑作为复发或化疗耐药老年淋巴瘤患者自体干细胞移植前的预处理方案：一项可行性试验（SAKK 37/05）
Hematol Oncol. 2017 Dec;35(4):576-583. doi: 10.1002/hon.2348. Epub 2016 Sep 28.
5
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.老年淋巴瘤患者的大剂量化疗与自体干细胞移植
Curr Oncol Rep. 2015 Sep;17(9):42. doi: 10.1007/s11912-015-0465-x.
6
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.新型抗体偶联药物在淋巴瘤中的新用途。
Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14.
7
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.异环磷酰胺、依托泊苷、阿糖胞苷和地塞米松作为挽救治疗，随后进行大剂量环磷酰胺、美法仑和依托泊苷联合自体外周血干细胞移植用于复发或难治性淋巴瘤。
Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x.
8
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.全身照射（TBI）预处理与非TBI预处理在初诊或复发的成熟T细胞和NK细胞非霍奇金淋巴瘤自体干细胞移植中的比较
Cancer Res Treat. 2017 Jan;49(1):92-103. doi: 10.4143/crt.2015.476. Epub 2016 May 9.
9
Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.对于复发和难治性霍奇金淋巴瘤，可以通过大剂量化疗和自体干细胞移植来克服化疗耐药性。
Ann Oncol. 2014 Nov;25(11):2218-2223. doi: 10.1093/annonc/mdu387. Epub 2014 Aug 22.
10
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.131I 标记利妥昔单抗放射免疫治疗联合 BEAM 预处理及自体造血干细胞移植挽救治疗复发/难治侵袭性非霍奇金淋巴瘤。
Cancer Biother Radiopharm. 2012 Nov;27(9):552-60. doi: 10.1089/cbr.2012.1275. Epub 2012 Oct 12.
引用本文的文献
1
Lymphoma and Long-Term cardiovascular disease risk: A comprehensive analysis from the UK biobank.淋巴瘤与长期心血管疾病风险：来自英国生物银行的综合分析
Ann Hematol. 2025 Aug 25. doi: 10.1007/s00277-025-06544-2.
2
Prompt Autologous Hematopoietic Stem Cell Transplant in Patients With Large B-Cell Lymphoma Is Associated With Lower Rates of Progression of Disease Prior to Transplant.在大B细胞淋巴瘤患者中进行即时自体造血干细胞移植与移植前疾病进展率较低相关。
EJHaem. 2025 Jul 24;6(4):e70108. doi: 10.1002/jha2.70108. eCollection 2025 Aug.
3
What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.我们在人类医学中对犬淋巴瘤模型的已知与未知——当前的知识状况
Cancers (Basel). 2025 Feb 10;17(4):596. doi: 10.3390/cancers17040596.
4
Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy.淋巴细胞恶性肿瘤异基因干细胞移植的预后因素及治疗结果
Blood Res. 2025 Feb 10;60(1):12. doi: 10.1007/s44313-025-00060-y.
5
Primary Sacral Activated B-Cell Like Diffuse Large B-Cell Lymphoma, Triple Expressor Type: A Case Report with Literature Review.原发性骶骨活化B细胞样弥漫性大B细胞淋巴瘤，三表达型：一例报告并文献复习
J Microsc Ultrastruct. 2022 Dec 1;12(4):228-231. doi: 10.4103/jmau.jmau_64_22. eCollection 2024 Oct-Dec.
6
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.与BEAM方案相比，基于米托蒽醌的新型预处理方案可使外周T细胞淋巴瘤患者获得显著的生存获益。
Cancer Med. 2024 Dec;13(23):e70476. doi: 10.1002/cam4.70476.
7
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms.基于性别的治疗相关髓系肿瘤风险差异。
J Clin Oncol. 2024 Nov;42(31):3739-3750. doi: 10.1200/JCO-24-01487. Epub 2024 Aug 2.
8
Causal association of circulating immune cells and lymphoma: A Mendelian randomization study.循环免疫细胞与淋巴瘤的因果关联：一项孟德尔随机化研究。
Open Med (Wars). 2024 Jul 15;19(1):20240984. doi: 10.1515/med-2024-0984. eCollection 2024.
9
BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.BeEAM 方案与 BEAM 方案：评价自体造血干细胞移植治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者的预处理方案。
Ann Hematol. 2024 Jul;103(7):2455-2462. doi: 10.1007/s00277-024-05813-w. Epub 2024 May 29.
10
Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas.优化的 BEAC 预处理方案改善非霍奇金淋巴瘤患者自体造血干细胞移植的临床结局。
Int J Hematol. 2024 Jul;120(1):96-105. doi: 10.1007/s12185-024-03755-7. Epub 2024 Apr 8.
本文引用的文献
1
Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.自然杀伤/T细胞淋巴瘤的临床特征与当前最佳治疗方案
Hematol Oncol Clin North Am. 2017 Apr;31(2):239-253. doi: 10.1016/j.hoc.2016.11.007. Epub 2017 Jan 30.
2
Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.自体造血干细胞移植治疗弥漫性大B细胞淋巴瘤
J Clin Exp Hematop. 2016;56(2):100-108. doi: 10.3960/jslrt.56.100.
3
State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.晚期弥漫性大B细胞淋巴瘤的前沿治疗方法
Hematol Oncol Clin North Am. 2016 Dec;30(6):1147-1162. doi: 10.1016/j.hoc.2016.07.002.
4
Nivolumab in the Treatment of Hodgkin Lymphoma.纳武利尤单抗治疗霍奇金淋巴瘤。
Clin Cancer Res. 2017 Apr 1;23(7):1623-1626. doi: 10.1158/1078-0432.CCR-16-1387. Epub 2016 Nov 23.
5
Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies.转化型低度淋巴瘤异体与自体干细胞移植的疗效比较：比较研究的系统评价与汇总分析
Acta Haematol. 2016;136(4):244-255. doi: 10.1159/000449031. Epub 2016 Nov 2.
6
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.弥漫性大B细胞淋巴瘤患者自体干细胞移植后复发的结局：CORAL研究纳入患者的分析
Bone Marrow Transplant. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.
7
2016 US lymphoid malignancy statistics by World Health Organization subtypes.2016年按世界卫生组织亚型分类的美国淋巴系统恶性肿瘤统计数据。
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. doi: 10.3322/caac.21357. Epub 2016 Sep 12.
8
Treatment of relapsed and refractory Hodgkin Lymphoma.复发难治性霍奇金淋巴瘤的治疗
Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12.
9
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
10
The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.血清乳酸脱氢酶升高的晚期弥漫性大B细胞淋巴瘤患者中，根据前期自体干细胞移植进行分子分类的不同作用
Ann Hematol. 2016 Sep;95(9):1491-501. doi: 10.1007/s00277-016-2729-4. Epub 2016 Jun 21.
Zotero 插件